Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Obesity 2Infertility 2Glioblastoma 2Endometrial Neoplasms 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1TP53 Y220C Mutation 1Sarcoma, Ewing 1Sarcoma 1Prostate Cancer Recurrent 1Progression-Free Survival 1Preleukemia 1Posterior Fossa Ependymal Tumor 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Metabolic Diseases 1Medulloblastoma 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Hyperandrogenism 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × TP53 Y220C Mutation × Metformin × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡